Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review H1 2015


#308807

92pages

GlobalData

$ 2500

In Stock

Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015

Summary

GlobalData's clinical trial report, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Global Clinical Trials Review, H1, 2015" provides an overview of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Datas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 7
Report Guidance 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Unaccomplished Trials of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 26
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials 32
Prominent Drugs 33
Latest Clinical Trials News on Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 34
Jun 02, 2015: Discovery of breakthrough MRSA compound 34
May 21, 2015: ContraFect Announces First Healthy Volunteer Dosed With CF-301 34
Apr 29, 2015: ContraFect Announces Commencement of Phase 1 Clinical Trial of CF-301 for Staph Bloodstream Infections, Including MRSA 35
Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance 35
Apr 24, 2015: New Data Shows Greater In Vitro Potency for VIBATIV (Telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, Compared to Alternative Antibiotic Treatments 36
Apr 16, 2015: Theravance Biopharma to Present New Data Highlighting in vitro Potency of VIBATIV (telavancin) Against Multidrug-Resistant Gram-Positive Bacteria, Including MRSA, at 2015 ECCMID Conference 37
Clinical Trial Profiles 39
Clinical Trial Overview of Top Companies 39
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Khorakiwala Holdings and Investments Private Limited 40
Clinical Trial Overview of Khorakiwala Holdings and Investments Private Limited 40
AstraZeneca Plc 41
Clinical Trial Overview of AstraZeneca Plc 41
GlaxoSmithKline Plc 42
Clinical Trial Overview of GlaxoSmithKline Plc 42
Forest Laboratories, Inc. (Inactive) 43
Clinical Trial Overview of Forest Laboratories, Inc. (Inactive) 43
Cubist Pharmaceuticals, Inc. (Inactive) 44
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. (Inactive) 44
Nabriva Therapeutics AG 45
Clinical Trial Overview of Nabriva Therapeutics AG 45
MicuRx Pharmaceuticals, Inc. 46
Clinical Trial Overview of MicuRx Pharmaceuticals, Inc. 46
Jaguar Holding Company II 47
Clinical Trial Overview of Jaguar Holding Company II 47
Enanta Pharmaceuticals, Inc. 48
Clinical Trial Overview of Enanta Pharmaceuticals, Inc. 48
Clinical Trial Overview of Top Institutes / Government 49
University of California, Irvine 49
Clinical Trial Overview of University of California, Irvine 49
Washington University School of Medicine 50
Clinical Trial Overview of Washington University School of Medicine 50
Ann & Robert H. Lurie Childrens Hospital of Chicago 51
Clinical Trial Overview of Ann & Robert H. Lurie Childrens Hospital of Chicago 51
Assistance Publique - Hopitaux de Paris 52
Clinical Trial Overview of Assistance Publique - Hopitaux de Paris 52
Menzies School of Health Research 53
Clinical Trial Overview of Menzies School of Health Research 53
Seoul National University Bundang Hospital 54
Clinical Trial Overview of Seoul National University Bundang Hospital 54
Uniformed Services University of the Health Sciences 55
Clinical Trial Overview of Uniformed Services University of the Health Sciences 55
University Hospital, Geneva 56
Clinical Trial Overview of University Hospital, Geneva 56
University Medicine Greifswald 57
Clinical Trial Overview of University Medicine Greifswald 57
Wilford Hall Medical Center 58
Clinical Trial Overview of Wilford Hall Medical Center 58
Five Key Clinical Profiles 59
Appendix 89
Abbreviations 89
Definitions 89
Research Methodology 90
Secondary Research 90
About GlobalData 91
Contact Us 91
Disclaimer 91
Source 92

List of Tables
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2015* 8
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 11
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 12
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2015* 13
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 14
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2015* 15
Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 16
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 19
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2015* 22
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 23
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Suspended Clinical Trials, 2015* 26
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Withdrawn Clinical Trials, 2015* 27
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Terminated Clinical Trials, 2015* 28
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 30
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 39
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Khorakiwala Holdings and Investments Private Limited, 2015* 40
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca Plc, 2015* 41
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline Plc, 2015* 42
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Forest Laboratories, Inc. (Inactive), 2015* 43
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc. (Inactive), 2015* 44
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Nabriva Therapeutics AG, 2015* 45
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by MicuRx Pharmaceuticals, Inc., 2015* 46
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Jaguar Holding Company II, 2015* 47
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Enanta Pharmaceuticals, Inc., 2015* 48
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Irvine, 2015* 49
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2015* 50
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Ann & Robert H. Lurie Childrens Hospital of Chicago, 2015* 51
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2015* 52
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Menzies School of Health Research, 2015* 53
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Bundang Hospital, 2015* 54
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Uniformed Services University of the Health Sciences, 2015* 55
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Geneva, 2015* 56
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by University Medicine Greifswald, 2015* 57
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials Market, Global, Clinical Trials by Wilford Hall Medical Center, 2015* 58

List of Figures
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2015* 8
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 9
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 10
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 11
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 12
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 13
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 14
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2015* 15
Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2015* 16
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 17
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 18
Proportion of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2015* 19
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 20
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 21
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2015* 22
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 23
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2015* 24
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2015* 25
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 29
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 30
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 31
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 32
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 33
GlobalData Methodology 90